Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 3, 2008, Pages 300-307

  Halabi, Susan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Binary endpoint; Phase III trials; Prostate cancer; Sample size; Survival endpoint

Indexed keywords

ANALYTICAL ERROR; CANCER SURVIVAL; DATA ANALYSIS; HUMAN; HYPOTHESIS; KAPLAN MEIER METHOD; MASKING; METHODOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RANDOM SAMPLE; RANDOMIZATION; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME;

CLINICAL TRIALS, PHASE III AS TOPIC; ELIGIBILITY DETERMINATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SAMPLE SIZE; SURVIVAL RATE;

EID: 42949119320     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.11.007     Document Type: Review

References (40)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Ries L.A.G., Eisner M.P., Kosary C.L., et al. SEER cancer statistics review 1973-1998. NIH Pub. No. 00-2789 (2000), National Cancer Institute, Bethesda (MD)
3. Scher H.I., Mazumdar M., and Kelly W.K. Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 88 (1996) 1623-1634
4. Halabi S., Small E.J., Vogelzang N.J., et al. Impact of race on survival in men with metastatic hormone refractory prostate cancer. Urology 64 (2004) 212-217
5. Scher H.I., Eisenberger M., D'Amico A.V., et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA: Recommendations from the prostate-specific antigen working group. J Clin Oncol 22 (2004) 537-556
6. Petrylak D.P., Tangen C.M., Hussain M.H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
7. Simon R.S. Design and conduct of clinical trials. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles and practice of oncology (1993), Lippincott, Philadelphia (PA) 418-440
8. Amato D.A. The design and analysis of equivalence trials. In: Finkelstein D.M., and Schoenfeld D.A. (Eds). AIDS clinical trials (1995), Wiley-Liss, Inc, New York (NY) 155-176
9. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: The results of CALGB 9182. J Clin Oncol 17 (1999) 2506-2513
10. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
11. Johnson J.R., Williams G., and Pazdur R. Endpoints and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 7 (2003) 1404-1411
12. Dagher R., Johnson J., Williams G., et al. Accelerated approval of oncology products: A decade of experience. J Natl Cancer Inst 96 (2004) 1500-1509
13. Feigl P., Blumenstein B., Thompson I., et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 16 (1995) 150-163
14. Tangen C.T., Goodman P.J., Crowley J.J., et al. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. J Urol 171 (2004) S64-S67
15. Small E.J., Halabi S., Ratain M.J., et al. A randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of intergroup 0159 (CALGB 9480). J Clin Oncol 20 (2002) 3369-3375
16. Small E.J., Halabi S., Dawson N., et al. A phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: Results of CALGB 9583. J Clin Oncol 22 (2004) 1025-1033
17. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
18. Ahles T.A., Herndon II J.E., Small E.J., et al. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma. Cancer 101 (2004) 2202-2208
19. Pocock S.J. Allocation of patients in clinical trials. Biometrics 35 (1979) 183-197
20. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34 (1976) 585-612
21. Halabi S., Small E.J., Kantoff P.W., et al. A prognostic model for predicting overall survival in men with advanced prostate cancer. J Clin Oncol 21 (2003) 1232-1237
22. George S.L., and Desu M.M. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis 27 (1974) 15-29
23. Rubinstein L.V., Gail M.H., Santner T.J., et al. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis 34 (1981) 469-479
24. Chen T.T., and Simon R. Extension of two-sided test to multiple treatment trials. Communications in Statistics, Part A - Theory and Methods 25 (1996) 947-965
25. Chen T.T., and Simon R.M. Extension of one-sided test to multiple treatment trials. Control Clin Trials 15 (1994) 124-134
26. Halabi S., and Singh B. Sample size determination for comparing several survival curves with unequal allocations. Stat Med 23 (2004) 1793-1815
27. Peterson B., and George S.L. Sample size requirements and length of study for testing interaction in a 2 × k factorial design when time-to-failure is the outcome [corrected]. Control Clin Trials 14 (1993) 511-522
28. Casagrande J.T., Pike M.C., and Smith P.G. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 34 (1978) 483-486
29. McPherson K., and Armitage P. Repeated significance tests on accumulating data when the null hypothesis is not true. J Royal Stat Soc A 134 (1971) 15-25
30. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
31. Lan K.K.G., and DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika 70 (1983) 659-663
32. Emerson S., and Fleming T.R. Symmetric group sequential test designs. Biometrics 45 (1989) 905-923
33. Freidlin B., Korn E., and George S. Data monitoring committees and interim monitoring guidelines. Control Clin Trials 20 (1999) 395-407
34. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
35. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Analysis and examples. Br J Cancer 35 (1977) 1-39
36. Cox D.R. Regression models and life tables. J Royal Statistical Society B 34 (1972) 187-220
37. Tibshirani R. A plain man's guide to the proportional hazards model. Clin Invest Med 5 (1982) 63-68
38. Anderson J.R., Cain K.C., and Gelber R.D. Analysis of survival by tumor response. J Clin Oncol 1 (1983) 710-719
39. Gray R.J. A class of k sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1999) 1141-1154
40. Pepe M., and Mori M. Kaplan-Meier marginal or conditional probability curves in summarizing competing risks failure time data. Stat Med 12 (1993) 737-751